We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · September 29, 2022

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone for Newly Diagnosed Multiple Myeloma

British Journal of Haematology


Additional Info

British Journal of Haematology
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Br. J. Haematol 2022 Sep 16;[EPub Ahead of Print], DW Sborov, M Baljevic, B Reeves, J Laubach, YA Efebera, C Rodriguez, LJ Costa, A Chari, R Silbermann, SA Holstein, LD Anderson, JL Kaufman, N Shah, H Pei, S Patel, A Cortoos, JB Bartlett, J Vermeulen, TS Lin, PM Voorhees, PG Richardson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading